edoc

Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement

Domínguez, J. and Boeree, M. J. and Cambau, E. and Chesov, D. and Conradie, F. and Cox, V. and Dheda, K. and Dudnyk, A. and Farhat, M. R. and Gagneux, S. and Grobusch, M. P. and Gröschel, M. I. and Guglielmetti, L. and Kontsevaya, I. and Lange, B. and van Leth, F. and Lienhardt, C. and Mandalakas, A. M. and Maurer, F. P. and Merker, M. and Miotto, P. and Molina-Moya, B. and Morel, F. and Niemann, S. and Veziris, N. and Whitelaw, A. and Horsburgh, C. R. and Jr., and Lange, C. and TBnet, and Resist-TB networks, . (2023) Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement. The Lancet infectious diseases, 23 (4). e122-e137.

Full text not available from this repository.

Official URL: https://edoc.unibas.ch/94527/

Downloads: Statistics Overview

Abstract

Drug-resistant tuberculosis is a substantial health-care concern worldwide. Despite culture-based methods being considered the gold standard for drug susceptibility testing, molecular methods provide rapid information about the Mycobacterium tuberculosis mutations associated with resistance to anti-tuberculosis drugs. This consensus document was developed on the basis of a comprehensive literature search, by the TBnet and RESIST-TB networks, about reporting standards for the clinical use of molecular drug susceptibility testing. Review and the search for evidence included hand-searching journals and searching electronic databases. The panel identified studies that linked mutations in genomic regions of M tuberculosis with treatment outcome data. Implementation of molecular testing for the prediction of drug resistance in M tuberculosis is key. Detection of mutations in clinical isolates has implications for the clinical management of patients with multidrug-resistant or rifampicin-resistant tuberculosis, especially in situations when phenotypic drug susceptibility testing is not available. A multidisciplinary team including clinicians, microbiologists, and laboratory scientists reached a consensus on key questions relevant to molecular prediction of drug susceptibility or resistance to M tuberculosis, and their implications for clinical practice. This consensus document should help clinicians in the management of patients with tuberculosis, providing guidance for the design of treatment regimens and optimising outcomes.
Faculties and Departments:09 Associated Institutions > Swiss Tropical and Public Health Institute (Swiss TPH)
09 Associated Institutions > Swiss Tropical and Public Health Institute (Swiss TPH) > Department of Medical Parasitology and Infection Biology (MPI) > Tuberculosis Ecology and Evolution Unit (Gagneux)
UniBasel Contributors:Gagneux, Sebastien
Item Type:Article, refereed
Article Subtype:Research Article
ISSN:1473-3099
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:09 May 2023 06:25
Deposited On:09 May 2023 06:25

Repository Staff Only: item control page